Advertisement

Usefulness of Transient and Persistent No Reflow to Predict Adverse Clinical Outcomes Following Percutaneous Coronary Intervention

Published:December 19, 2011DOI:https://doi.org/10.1016/j.amjcard.2011.09.037
      The no reflow phenomenon is reported to occur in >2% of all percutaneous coronary interventions (PCIs) and portends a poor prognosis. We analyzed data from 5,286 consecutive patients who underwent PCI from the Melbourne Interventional Group (MIG) registry from April 2004 through January 2008 who had 30-day follow-up completed. Patients without no reflow (normal reflow, n = 5,031) were compared to 255 (4.8%) with no reflow (n = 217 for transient no reflow, n = 38 for persistent no reflow). Patients with transient or persistent no reflow were more likely to present with ST-elevation myocardial infarction (MI) or cardiogenic shock (p <0.0001 for the 2 comparisons). They were also more likely to have complex lesions (American College of Cardiology/American Heart Association type B2/C), have lesions within a bypass graft, require an intra-aortic balloon pump, receive glycoprotein IIb/IIIa inhibition, and have a longer mean stent length (p <0.0001 for all comparisons). In-hospital outcomes were significantly worse in those patients with transient or persistent no reflow, with increased death, periprocedural MI, renal impairment, and major adverse cardiac events (p <0.0001 for all comparisons). Similarly, transient and persistent no reflow portended worse 30-day clinical outcomes, with a progressive increase in mortality (normal reflow 1.7% vs transient no reflow 5.5% vs persistent no reflow 13.2%, p <0.0001), MI, target vessel revascularization, and major adverse cardiac events (p <0.0001 for all comparisons) compared to patients with normal flow. In conclusion, transient or persistent no reflow complicates approximately 1 in 20 PCIs and results in stepwise increases in in-hospital and 30-day adverse outcomes.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Morishima I.
        • Sone T.
        • Okumura K.
        • Tsuboi H.
        • Kondo J.
        • Mukawa H.
        • Matsui H.
        • Toki Y.
        • Ito T.
        • Hayakawa T.
        Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction.
        J Am Coll Cardiol. 2000; 36: 1202-1209
        • Ndrepepa G.
        • Tiroch K.
        • Keta D.
        • Fusaro M.
        • Seyfarth M.
        • Pache J.
        • Mehilli J.
        • Schömig A.
        • Kastrati A.
        Predictive factors and impact of no reflow after primary percutaneous coronary intervention in patients with acute myocardial infarction.
        Circ Cardiovasc Interv. 2010; 3: 27-33
        • Yip H.K.
        • Chen M.C.
        • Chang H.W.
        • Hang C.L.
        • Hsieh Y.K.
        • Fang C.Y.
        • Wu C.J.
        Angiographic morphologic features of infarct-related arteries and timely reperfusion in acute myocardial infarction: predictors of slow-flow and no-reflow phenomenon.
        Chest. 2002; 122: 1322-1332
        • Iwakura K.
        • Ito H.
        • Kawano S.
        • Shintani Y.
        • Yamamoto K.
        • Kato A.
        • Ikushima M.
        • Tanaka K.
        • Kitakaze M.
        • Hori M.
        • Higashino Y.
        • Fujii K.
        Predictive factors for development of the no-reflow phenomenon in patients with reperfused anterior wall acute myocardial infarction.
        J Am Coll Cardiol. 2001; 38: 472-477
        • Ajani A.E.
        • Szto G.
        • Duffy S.J.
        • Eccleston D.
        • Clark D.J.
        • Lefkovits J.
        • Chew D.P.
        • Warren R.
        • Black A.
        • New G.
        • Walton A.
        • Lew R.
        • Shaw J.
        • Horrigan M.
        • Sebastian M.
        • Yan B.P.
        • Brennan A.
        • Meehan A.
        • Reid C.
        • Krum H.
        • Melbourne Interventional Group Investigators
        The foundation and launch of the Melbourne Interventional Group: a collaborative interventional cardiology project.
        Heart Lung Circ. 2006; 15: 44-47
        • Chan W.
        • Clark D.J.
        • Ajani A.E.
        • Yap C.H.
        • Andrianopoulos N.
        • Brennan A.L.
        • Dinh D.T.
        • Shardey G.C.
        • Smith J.A.
        • Reid C.M.
        • Duffy S.J.
        Progress towards a National Cardiac Procedure database—development of the Australasian Society of Cardiac and Thoracic Surgeons (ASCTS) and Melbourne Interventional Group (MIG) registries.
        Heart Lung Circ. 2011; 20: 10-18
        • Lagerqvist B.
        • James S.K.
        • Stenestrand U.
        • Lindbäck J.
        • Nilsson T.
        • Wallentin L.
        • SCAAR Study Group
        Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden.
        N Engl J Med. 2007; 356: 1009-1019
        • Andrianopoulos N.
        • Dinh D.
        • Duffy S.J.
        • Clark D.J.
        • Brennan A.L.
        • Chan W.
        • Shardey G.C.
        • Smith J.A.
        • Yap C.H.
        • Buxton B.F.
        • Ajani A.E.
        • Reid C.M.
        Quality control activities associated with registries in interventional cardiology and surgery.
        Heart Lung Circ. 2011; 20: 180-186
        • Butler M.J.
        • Eccleston D.
        • Clark D.J.
        • Ajani A.E.
        • Andrianopoulos N.
        • Brennan A.
        • New G.
        • Black A.
        • Szto G.
        • Reid C.M.
        • Yan B.P.
        • Shaw J.A.
        • Dart A.M.
        • Duffy S.J.
        • Melbourne Interventional Group
        The effect of intended duration of clopidogrel use on early and late mortality and major adverse cardiac events in patients with drug-eluting stents.
        Am Heart J. 2009; 157: 899-907
        • TIMI Study Group
        Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction.
        N Engl J Med. 1989; 320: 618-627
        • Mehta R.H.
        • Harjai K.J.
        • Boura J.
        • Cox D.
        • Stone G.W.
        • O'Neill W.
        • Grines C.L.
        • Primary Angioplasty in Myocardial Infarction (PAMI) Investigators
        Prognostic significance of transient no-reflow during primary percutaneous coronary intervention for ST-elevation acute myocardial infarction.
        Am J Cardiol. 2003; 92: 1445-1447
        • Piana R.N.
        • Paik G.Y.
        • Moscucci M.
        • Cohen D.J.
        • Gibson C.M.
        • Kugelmass A.D.
        • Carrozza Jr, J.P.
        • Kuntz R.E.
        • Baim D.S.
        Incidence and treatment of “no-reflow” after percutaneous coronary intervention.
        Circulation. 1994; 89: 2514-2518
        • Resnic F.S.
        • Wainstein M.
        • Lee M.K.
        • Behrendt D.
        • Wainstein R.V.
        • Ohno-Machado L.
        • Kirshenbaum J.M.
        • Rogers C.D.
        • Popma J.J.
        • Piana R.
        No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention.
        Am Heart J. 2003; 145: 42-46
        • Abbo K.M.
        • Dooris M.
        • Glazier S.
        • O'Neill W.W.
        • Byrd D.
        • Grines C.L.
        • Safian R.D.
        Features and outcome of no-reflow after percutaneous coronary intervention.
        Am J Cardiol. 1995; 75: 778-782
        • Lee C.H.
        • Wong H.B.
        • Tan H.C.
        • Zhang J.J.
        • Teo S.G.
        • Ong H.Y.
        • Low A.
        • Sutandar A.
        • Lim Y.T.
        Impact of reversibility of no reflow phenomenon on 30-day mortality following percutaneous revascularization for acute myocardial infarction-insights from a 1,328 patient registry.
        J Interv Cardiol. 2005; 18: 261-266
        • Galiuto L.
        • Lombardo A.
        • Maseri A.
        • Santoro L.
        • Porto I.
        • Cianflone D.
        • Rebuzzi A.G.
        • Crea F.
        Temporal evolution and functional outcome of no reflow: sustained and spontaneously reversible patterns following successful coronary recanalisation.
        Heart. 2003; 89: 731-737
        • Hoffmann R.
        • Haager P.
        • Arning J.
        • Christott P.
        • Radke P.
        • Blindt R.
        • Ortlepp J.
        • Lepper W.
        • Hanrath P.
        Usefulness of myocardial blush grade early and late after primary coronary angioplasty for acute myocardial infarction in predicting left ventricular function.
        Am J Cardiol. 2003; 92: 1015-1019
        • Webb J.G.
        • Carere R.G.
        • Virmani R.
        • Baim D.
        • Teirstein P.S.
        • Whitlow P.
        • McQueen C.
        • Kolodgie F.D.
        • Buller E.
        • Dodek A.
        • Mancini G.B.
        • Oesterle S.
        Retrieval and analysis of particulate debris after saphenous vein graft intervention.
        J Am Coll Cardiol. 1999; 34: 468-475
        • Cura F.A.
        • Bhatt D.L.
        • Lincoff A.M.
        • Kapadia S.R.
        • L'Allier P.L.
        • Ziada K.M.
        • Wolski K.E.
        • Moliterno D.J.
        • Brener S.J.
        • Ellis S.G.
        • Topol E.J.
        Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions.
        Circulation. 2000; 102: 28-34
        • de Lemos J.A.
        • Antman E.M.
        • Gibson C.M.
        • McCabe C.H.
        • Giugliano R.P.
        • Murphy S.A.
        • Coulter S.A.
        • Anderson K.
        • Scherer J.
        • Frey M.J.
        • Van Der Wieken R.
        • Van De Werf F.
        • Braunwald E.
        Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction.
        Circulation. 2000; 101: 239-243
        • Eeckhout E.
        • Kern M.J.
        The coronary no-reflow phenomenon: a review of mechanisms and therapies.
        Eur Heart J. 2001; 22: 729-739
        • Gibson C.M.
        • Schömig A.
        Coronary and myocardial angiography: angiographic assessment of both epicardial and myocardial perfusion.
        Circulation. 2004; 109: 3096-3105
        • Niccoli G.
        • Burzotta F.
        • Galiuto L.
        • Crea F.
        Myocardial no-reflow in humans.
        J Am Coll Cardiol. 2009; 54: 281-292
        • Wu K.C.
        • Zerhouni E.A.
        • Judd R.M.
        • Lugo-Olivieri C.H.
        • Barouch L.A.
        • Schulman S.P.
        • Blumenthal R.S.
        • Lima J.A.
        Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction.
        Circulation. 1998; 97: 765-772
        • Baim D.S.
        • Wahr D.
        • George B.
        • Leon M.B.
        • Greenberg J.
        • Cutlip D.E.
        • Kaya U.
        • Popma J.J.
        • Ho K.K.
        • Kuntz R.E.
        • Saphenous vein graft Angioplasty Free of Emboli Randomized (SAFER) Trial Investigators
        Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts.
        Circulation. 2002; 105: 1285-1290
        • Vlaar P.J.
        • Svilaas T.
        • van der Horst I.C.
        • Diercks G.F.
        • Fokkema M.L.
        • de Smet B.J.
        • van den Heuvel A.F.
        • Anthonio R.L.
        • Jessurun G.A.
        • Tan E.S.
        • Suurmeijer A.J.
        • Zijlstra F.
        Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous Coronary Intervention in Acute Myocardial Infarction Study (TAPAS): a 1-year follow-up study.
        Lancet. 2008; 371: 1915-1920